Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy

OncoImmunology

Volumn 3, Issue 11, 2014, Pages e962401-1-e962401-3

  Lutz, Eric R ^a,b   Kinkead, Heather ^a,b   Jaffee, Elizabeth M ^a,b,c   Zheng, Lei ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NONE

Author keywords

pancreatic cancer; tumor immunotherapy; tumor vaccines

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; PROGRAMMED DEATH 1 LIGAND 1;

ARTICLE; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION; VACCINATION;

EID: 84938635509     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.962401     Document Type: Article

References (20)

1. R.Siegel, J.Ma, Z.Zou, A.Jemal. Cancer statistics, 2014. CA: Cancer J Clini 2014; 64(1):9-29; http://dx.doi.org/10.1017/S0009840X13002084
2. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010; 363(8):711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
3. J.R.Brahmer, S.S.Tykodi, L.Q.Chow, W.J.Hwu, S.L.Topalian, P.Hwu, C.G.Drake, L.H.Camacho, J.Kauh, K.Odunsi Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl J Med 2012; 366(26):2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
4. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med 2012; 366(26):2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
5. O.Hamid, C.Robert, A.Daud, F.S.Hodi, W.J.Hwu, R.Kefford, J.D.Wolchok, P.Hersey, R.W.Joseph, J.S.Weber Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New Engl J Med 2013; 369(2):134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
6. R.E.Royal, C.Levy, K.Turner, A.Mathur, M.Hughes, U.S.Kammula, R.M.Sherry, S.L.Topalian, J.C.Yang, I.Lowy Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33(8):828-33; PMID:20842054; http://dx.doi.org/10.1097/CJI.0b013e3181eec14c
7. J.M.Taube, A.Klein, J.R.Brahmer, H.Xu, X.Pan, J.H.Kim, L.Chen, D.M.Pardoll, S.L.Topalian, R.A.Anders. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20(19):5064-74; PMID:24714771
8. L.Zheng, J.Xue, E.M.Jaffee, A.Habtezion. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterol 2013; 144(6):1230-40; http://dx.doi.org/10.1053/j.gastro.2012.12.042
9. E.M.Jaffee, M.Schutte, J.Gossett, L.A.Morsberger, A.J.Adler, M.Thomas, T.F.Greten, R.H.Hruban, C.J.Yeo, C.A.Griffin. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 1998; 4(3):194-203.; PMID:9612602
10. E.M.Jaffee, R.H.Hruban, B.Biedrzycki, D.Laheru, K.Schepers, P.R.Sauter, M.Goemann, J.Coleman, L.Grochow, R.C.Donehower Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol: Off J Am Soc Clin Oncol 2001; 19(1):145-56
11. D.Laheru, E.Lutz, J.Burke, B.Biedrzycki, S.Solt, B.Onners, I.Tartakovsky, J.Nemunaitis, D.Le, E.Sugar Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res: Off J Am Assoc Cancer Res 2008; 14(5):1455-63; http://dx.doi.org/10.1158/1078-0432.CCR-07-0371
12. E.Lutz, C.J.Yeo, K.D.Lillemoe, B.Biedrzycki, B.Kobrin, J.Herman, E.Sugar, S.Piantadosi, J.L.Cameron, S.Solt A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011; 253(2):328-35; PMID:21217520; http://dx.doi.org/10.1097/SLA.0b013e3181fd271c
13. E.R.Lutz, A.A.Wu, E.Bigelow, R.Sharma, G.Mo, K.Soares, S.Solt, A.Dorman, A.Wamwea, A.Yager Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014; 2(7):616-31; PMID:24942756; http://dx.doi.org/10.1158/2326-6066.CIR-14-0027
14. A.Cipponi, M.Mercier, T.Seremet, J.F.Baurain, I.Theate, J.van den Oord, M.Stas, T.Boon, P.G.Coulie, N.van Baren. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res 2012; 72(16):3997-4007; PMID:22850419; http://dx.doi.org/10.1158/0008-5472.CAN-12-1377
15. D.Coppola, M.Nebozhyn, F.Khalil, H.Dai, T.Yeatman, A.Loboda, J.J.Mule. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol 2011; 179(1):37-45; PMID:21703392; http://dx.doi.org/10.1016/j.ajpath.2011.03.007
16. M.C.Dieu-Nosjean, M.Antoine, C.Danel, D.Heudes, M.Wislez, V.Poulot, N.Rabbe, L.Laurans, E.Tartour, L.de Chaisemartin Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol: Off J Am Soc Clin Oncol 2008; 26(27):4410-17; http://dx.doi.org/10.1200/JCO.2007.15.0284
17. J.L.Messina, D.A.Fenstermacher, S.Eschrich, X.Qu, A.E.Berglund, M.C.Lloyd, M.J.Schell, V.K.Sondak, J.S.Weber, J.J.Mule. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012; 2:765; PMID:23097687; http://dx.doi.org/10.1038/srep00765
18. J.Goc, W.H.Fridman, C.Sautes-Fridman, M.C.Dieu-Nosjean. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunol 2013; 2(12):e26836; http://dx.doi.org/10.4161/onci.26836
19. J.M.Taube, R.A.Anders, G.D.Young, H.Xu, R.Sharma, T.L.McMiller, S.Chen, A.P.Klein, D.M.Pardoll, S.L.Topalian Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4(127):127ra137; http://dx.doi.org/10.1126/scitranslmed.3003689
20. D.T.Le, E.Lutz, J.N.Uram, E.A.Sugar, B.Onners, S.Solt, L.Zheng, L.A.DiazJr., R.C.Donehower, E.M.Jaffee Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36(7):382-9; PMID:23924790; http://dx.doi.org/10.1097/CJI.0b013e31829fb7a2